Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Elevai Labs, Inc. - Common Stock (NQ: ELAB )

0.1005 -0.0059 (-5.55%)
Streaming Delayed Price Updated: 2:39 PM EDT, Sep 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,140,523
Open 0.1008
Bid (Size) 0.1004 (116)
Ask (Size) 0.1005 (15)
Prev. Close 0.1064
Today's Range 0.0951 - 0.1045
52wk Range 0.1006 - 4.244
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Dow Gains Over 50 Points; Elevai Labs Shares Plummet
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Down Over 1%; US Manufacturing PMI Falls In September
Via Benzinga
Exposures Fossil Fuels

Performance

YTD
-94.68%
-94.68%
1 Month
-68.59%
-68.59%
3 Month
-82.82%
-82.82%
6 Month
-85.68%
-85.68%
1 Year
-97.04%
-97.04%

More News

Read More
Why Elevai Labs (ELAB) Stock Is Down 60% Today
Via Benzinga
US Stocks Edge Higher; Chicago Fed National Activity Increases In August
Via Benzinga
Topics Economy
Exposures Interest Rates
Elevai Labs Inc. Announces Pricing of $8.0 Million Public Offering
From Elevai Labs Inc.
Via GlobeNewswire
ELAB Stock Earnings: Elevai Labs Reported Results for Q2 2024
Via InvestorPlace
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Results for E-Series Exosome Technology in Potential Melasma Applications
From Elevai Labs Inc.
Via GlobeNewswire
Why GitLab Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Encouraging Data Results Indicating Potential for Hair Restoration Using Proprietary Exosome Technology
From Elevai Labs Inc.
Via GlobeNewswire
12 Consumer Staples Stocks Moving In Monday's After-Market Session
Via Benzinga
Elevai Labs Inc. Files Combination Patents with Yuva Biosciences for Breakthrough Hair and Scalp Care Technology Utilizing YuvaBioⓇ Y100™ Mitochondrial Innovation and Elevai Exosomes™
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare Inc., Announces Positive Data Results with Completion of Clinical Study of Elevai Enfinity™ Topical Exosome Serum
From Elevai Labs Inc.
Via GlobeNewswire
Why MIRA Pharmaceuticals Shares Are Trading Higher By Around 45%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Why Workday Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Elevai Labs Inc. Subsidiary, Elevai Research Inc., Announces Preliminary Positive Research Data Highlighting the Potential of Proprietary Exosome Technology for Skin Health Applications
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Biosciences, Continues to Advance its Scientific Advisory Board with the Appointment of Orian Shirihai, MD, PhD
From Elevai Labs Inc.
Via GlobeNewswire
Why Indivior Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
Top 4 Risk Off Stocks You'll Regret Missing In July
Via Benzinga
Elevai Labs Inc. Subsidiary, Elevai Skincare, Announces The Elevai S-Series Hair and Scalp Care Product Line
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc. Subsidiary, Elevai Skincare to Debut Upcoming New Product Line at The Aesthetic Show 2024
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Forms New Scientific Advisory Board for its Weight Loss Programs
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Subsidiary, Elevai Skincare, to Present at the Beauty Through Science Conference in Stockholm
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 Conference
From Elevai Labs Inc.
Via GlobeNewswire
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
Via News Direct
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.